ReviewAnalytical cellular pathology (Amsterdam)2016
Single-Cell Sequencing Technology in Oncology: Applications for Clinical Therapies and Research.
Review in Analytical cellular pathology (Amsterdam), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Review
- Exploring the role of neutrophil extracellular traps in colorectal cancer: Insights from single-cell sequencing.World journal of gastrointestinal oncology · 2025Review
- Single-cell sequencing: Current applications in various tuberculosis specimen types.Cell proliferation · 2024Review
- Recent progress and applications of single-cell sequencing technology in breast cancer.Frontiers in genetics · 2024Review
- Cutaneous Melanoma Classification: The Importance of High-Throughput Genomic Technologies.Frontiers in oncology · 2021Review
- High-dimension single-cell analysis applied to cancer.Molecular aspects of medicine · 2018Review
- Single-cell sequencing and tumorigenesis: improved understanding of tumor evolution and metastasis.Clinical and translational medicine · 2017Review
- Genetically Modified T-Cell-Based Adoptive Immunotherapy in Hematological Malignancies.Journal of immunology research · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cellular heterogeneity is a fundamental characteristic of many cancers. A lack of cellular homogeneity contributes to difficulty in designing targeted oncological therapies. Therefore, the development of novel methods to determine and characterize oncologic cellular heterogeneity is a critical next step in the development of novel cancer therapies. Single-cell sequencing (SCS) technology has been recently employed for analyzing the genetic polymorphisms of individual cells at the genome-wide level. SCS requires (1) precise isolation of the single cell of interest; (2) isolation and amplification of genetic material; and (3) descriptive analysis of genomic, transcriptomic, and epigenomic data. In addition to targeted analysis of single cells isolated from tumor biopsies, SCS technology may be applied to circulating tumor cells, which may aid in predicting tumor progression and metastasis. In this paper, we provide an overview of SCS technology and review the current literature on the potential application of SCS to clinical oncology and research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.